Edgewise Therapeutics Stock Alpha and Beta Analysis
| EWTX Stock | USD 31.98 0.03 0.09% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Edgewise Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Edgewise Therapeutics over a specified time horizon. Remember, high Edgewise Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Edgewise Therapeutics' market risk premium analysis include:
Beta 2.91 | Alpha 0.57 | Risk 7.65 | Sharpe Ratio 0.12 | Expected Return 0.95 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Edgewise |
Edgewise Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Edgewise Therapeutics market risk premium is the additional return an investor will receive from holding Edgewise Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Edgewise Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Edgewise Therapeutics' performance over market.| α | 0.57 | β | 2.91 |
Edgewise Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Edgewise Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Edgewise Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Edgewise Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Edgewise Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Edgewise Therapeutics shares will generate the highest return on investment. By understating and applying Edgewise Therapeutics stock market price indicators, traders can identify Edgewise Therapeutics position entry and exit signals to maximize returns.
Edgewise Therapeutics Return and Market Media
The median price of Edgewise Therapeutics for the period between Sat, Aug 24, 2024 and Fri, Nov 22, 2024 is 29.5 with a coefficient of variation of 24.63. The daily time series for the period is distributed with a sample standard deviation of 6.82, arithmetic mean of 27.71, and mean deviation of 5.96. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by John Moore of 23125 shares of Edgewise Therapeutics subject to Rule 16b-3 | 08/30/2024 |
2 | Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstru... | 09/17/2024 |
3 | Disposition of 20922 shares by John Moore of Edgewise Therapeutics at 27.6295 subject to Rule 16b-3 | 09/23/2024 |
4 | Orbimed Advisors LLC Adjusts Stake in Passage Bio Inc | 09/24/2024 |
5 | Edgewise Therapeutics CFO sells over 3.5 million in company stock | 09/25/2024 |
6 | Edgewise Therapeutics to Present on Sevasemten for Becker Muscular Dystrophy at the 29th International Annual Congress of the World Muscle Society | 10/01/2024 |
7 | Orbimed Advisors LLC Reduces Stake in TELA Bio Inc | 10/02/2024 |
8 | Dimensional Fund Advisors LP Increases Holdings in Edgewise Therapeutics, Inc. - MarketBeat | 10/08/2024 |
9 | Acquisition by Carruthers R Michael of 70000 shares of Edgewise Therapeutics at 0.71 subject to Rule 16b-3 | 10/11/2024 |
10 | Acquisition by Behrad Derakhshan of 4800 shares of Edgewise Therapeutics at 1.93 subject to Rule 16b-3 | 10/25/2024 |
11 | Edgewise Therapeutics stock hits 52-week high at 36.71 - Investing.com | 11/06/2024 |
12 | Edgewise Therapeutics Given New 45.00 Price Target at Wedbush | 11/11/2024 |
13 | How this Weeks Premium Top 10 Performed, November 15, 2024 | 11/15/2024 |
About Edgewise Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Edgewise or other stocks. Alpha measures the amount that position in Edgewise Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Edgewise Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Edgewise Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Edgewise Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Edgewise Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Edgewise Therapeutics. Please utilize our Beneish M Score to check the likelihood of Edgewise Therapeutics' management manipulating its earnings.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Edgewise Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Edgewise Stock Analysis
When running Edgewise Therapeutics' price analysis, check to measure Edgewise Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edgewise Therapeutics is operating at the current time. Most of Edgewise Therapeutics' value examination focuses on studying past and present price action to predict the probability of Edgewise Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edgewise Therapeutics' price. Additionally, you may evaluate how the addition of Edgewise Therapeutics to your portfolios can decrease your overall portfolio volatility.